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OBJECTIVES This study tested the hypothesis that angiotensin-converting enzyme (ACE) inhibitors
attenuate beta-adrenergic contractility in patients with idiopathic dilated cardiomyopathy
(DCM) through nitric oxide (NO) myocardial signaling.
BACKGROUND The ACE inhibitors increase bradykinin, an agonist of NO synthase (NOS). Nitric oxide
inhibits beta-adrenergic myocardial contractility in patients with heart failure.
METHODS The study patients were given the angiotensin-1 (AT-1) receptor antagonist losartan for one
week. The hemodynamic responses to intravenous dobutamine were determined before and
during intracoronary infusion of enalaprilat (0.2 mg/min) with and without the NOS
inhibitor NG-monomethyl-L-arginine (L-NMMA, 5 mg/min).
RESULTS In patients with DCM (n 5 8), dobutamine increased the peak rate of rise of left ventricular
pressure (1dP/dt) by 49 6 8% (p , 0.001) and ventricular elastance (Ees) by 53 6 16% (p ,
0.03). Co-infusion with enalaprilat decreased 1dP/dt to 26 6 12% and Ees to 22 6 17%
above baseline (p , 0.05), and this anti-adrenergic effect was reversed by L-NMMA
co-infusion (p , 0.05 vs. enalaprilat). In addition, intracoronary enalaprilat reduced left
ventricular end-diastolic pressure (LVEDP), but not left ventricular end-diastolic volume,
consistent with increased left ventricular distensibility. Infusion with L-NMMA before
enalaprilat in patients with DCM (n 5 5) prevented the reduction in 1dP/dt, Ees and
LVEDP. In patients with normal left ventricular function (n 5 5), enalaprilat did not inhibit
contractility or reduce LVEDP during dobutamine infusion.
CONCLUSIONS Enalaprilat attenuates beta-adrenergic contractility and enhances left ventricular distensibility
in patients with DCM, but not in subjects with normal left ventricular function. This
response is NO modulated and occurs in the presence of angiotensin receptor blockade. These
findings may have important clinical and pharmacologic implications for the use of ACE
inhibitors, AT-1 receptor antagonists and their combination in the treatment of heart failure.
(J Am Coll Cardiol 2001;38:429–35) © 2001 by the American College of Cardiology
Angiotensin-converting enzyme (ACE) inhibitors, a prin-
cipal therapy for patients with left ventricular dysfunction,
have been shown to reduce mortality and improve symp-
toms in several large, prospective, randomized clinical trials
(1). Angiotensin-converting enzyme, a dipeptidyl car-
boxypeptidase identical to kininase II, catalyzes the conver-
sion of angiotensin I to angiotensin II, and also degrades
bradykinin (2). Although the beneficial effects of ACE
inhibitors in the treatment of heart failure have been
attributed to numerous favorable neurohormonal and he-
modynamic consequences of angiotensin II reduction, the
pharmacologic contribution of bradykinin to the action of
this drug class remains unclear.
One way in which bradykinin may contribute to the
cardiac effects of ACE inhibition is through B2 receptor-
mediated activation of nitric oxide synthase (NOS). Nitric
oxide (NO) attenuates the positive inotropic response to
beta-adrenergic stimulation in humans (3) and in animal
models (4,5), and this effect appears to be augmented in the
setting of left ventricular dysfunction (6). The current study
tested the hypothesis that ACE inhibitors attenuate beta-
adrenergic contractility through myocardial NO signaling,
likely due to inhibition of bradykinin degradation. Because
NOS activity is increased in the failing ventricle, we further
hypothesized that ACE inhibition would attenuate beta-
adrenergic contractility to a greater extent in patients with
heart failure than in control subjects with normal left
ventricular function.
METHODS
Study group. We studied 13 patients (10 men and 3
women; mean 6 SD age 45 6 3 years) with nonischemic
dilated cardiomyopathy (DCM). All patients had ejection
fractions ,40% (by echocardiography or radionuclide ven-
triculography) and left ventricular end-diastolic dimensions
.55 mm, and none had coronary stenoses .50%. Patients
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were in New York Heart Association functional class II
(n 5 4), III (n 5 8) or IV (n 5 1) heart failure and were
receiving digitalis (n 5 8), diuretics (n 5 11), ACE
inhibitors (n 5 5), angiotensin receptor blockers (n 5 4)
and beta-blockers (n 5 1) before study enrollment.
The control group consisted of five patients (2 men and 3
women; mean 6 SD age 44 6 4 years) referred for
evaluation of atypical chest pain. None of these patients had
coronary disease, and all had normal left ventricular function
(ejection fraction .50% and left ventricular end-diastolic
dimension ,55 mm) and normal right heart filling pres-
sures.
Hemodynamic measurements. All study patients and
control subjects were treated with the angiotensin-II recep-
tor antagonist, type 1 (AT-1) losartan (50 mg/day) for one
week before the study. Patients already taking ACE inhib-
itors were withdrawn from them and converted to the
angiotensin receptor blocker. This was done so that the
acute administration of ACE inhibitors during the study
would occur in the presence of AT-1 receptor blockade,
thereby principally eliciting signaling pathways not associ-
ated with this receptor. This dose of losartan results in near
maximal inhibition of the pressor response to exogenous
angiotensin I and angiotensin II in humans (7,8), and
losartan has similar pharmacokinetic properties in healthy
control subjects and in patients with heart failure (9). After
diagnostic coronary angiography and ventriculography, a
7F, high-fidelity, micromanometer-tipped conductance
catheter (Millar Instruments, model no. SSD-769, Hous-
ton, Texas) was placed in the left ventricular apex for
simultaneous pressure and volume measurements. Femoral
artery pressure was monitored through a 7F side-arm sheath
(Cordis Laboratories, Miami, Florida). The electrocardio-
gram, femoral artery pressure, left ventricular pressure and
volume and peak rate of rise of left ventricular pressure
(1dP/dt) were digitally recorded. Each measurement rep-
resents the mean value of at least 30 consecutive sinus beats.
Hemodynamic analysis was performed using custom-
designed Matlab (Natick, Massachusetts) software.
Indexes of myocardial systolic and diastolic performance
were derived from signal-averaged steady state pressure–
volume data. To eliminate the requirement for graded
inferior vena cava balloon occlusion, we used a single-beat
estimation of the end-systolic pressure-volume relationship
and slope (ventricular elastance [Ees]). This method derives
a value for Ees based on steady state pressure-volume data
and has been validated in both animals and humans,
including patients with cardiomyopathy (10). Preload was
indexed by left ventricular end-diastolic volume (LVEDV)
and pressure (LVEDP), and afterload was indexed by
systemic vascular resistance and effective arterial elastance
(Ea; ratio of left ventricular systolic pressure to stroke
volume) (11).
Left ventricular diastolic relaxation rates were assessed by
the time constant tau, derived from high-fidelity, microma-
nometer pressure recordings. Both the Weiss formula (tau
ln) and the hybrid-logistic method (tau l), which is less
dependent on LVEDP, were used to derive tau (12).
Drug infusion protocols. Digitalis, diuretics and nitrates
were withheld from subjects for 12 h before the study.
Heparinized saline was infused intracoronarily at a rate of
2 ml/min. Heart rate was maintained constant by atrial
pacing at 20 to 30 beats/min above the baseline heart rate.
Once baseline 1dP/dt was recorded, dobutamine (Lilly,
Indianapolis, Indiana) was infused through the right fem-
oral vein for the remainder of the protocol and titrated to
increase 1dP/dt by .30% above baseline (7.9 6 1.0 mg/kg
body weight per min in patients with DCM and 2.6 6
0.2 mg/kg per min in normal control subjects, p , 0.01).
Dobutamine was considered to be at steady state when three
consecutive measurements of 1dP/dt were stable over a
period of 10 min. Using a Harvard pump, enalaprilat and
NG-monomethyl-L-arginine (L-NMMA) were directly in-
fused into the left main coronary artery. For group I (with
DCM, n 5 8) and group III (with normal left ventricular
function, n 5 5), enalaprilat (0.2 mg/min) was infused
intracoronarily for 15 min, followed immediately by co-
infusion with L-NMMA (5 mg/min [20 mmol/min]) for
15 min. To determine whether L-NMMA could prevent
the effects of enalaprilat, the order of intracoronary infusions
was reversed in group II (with DCM, n 5 5). Hemody-
namic measurements were recorded every 5 min during drug
infusion. Ees and 1dP/dt were recorded from all patients in
groups I and III. In group II, 1dP/dt was recorded in all
five patients, but Ees could only be measured in three
patients during baseline conditions and in two patients
during drug infusion.
Statistical analysis. All data are presented as the mean
value 6 SEM. Baseline characteristics between the three
groups of subjects were compared using one-way analysis of
variance or the Student t test, with the Bonferroni correc-
tion. Changes within a single group with successive drug
infusions were analyzed by paired two-way analysis of
variance, using an identification term for each patient. Post
hoc testing was performed using the Student-Newman-
Keuls test.
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
AT-1 5 angiotensin-II receptor, type 1
DCM 5 dilated cardiomyopathy
1dP/dt 5 peak rate of rise of left ventricular pressure
Ea 5 arterial elastance
Ees 5 ventricular elastance
LVEDP 5 left ventricular end-diastolic pressure
LVEDV 5 left ventricular end-diastolic volume
L-NMMA 5 NG-monomethyl-L-arginine
NO 5 nitric oxide
NOS 5 nitric oxide synthase
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RESULTS
Baseline hemodynamic data. Baseline hemodynamic
measurements for patients with DCM (groups I and II, n 5
13) and patients with normal left ventricular function
(group III, n 5 5) are shown in Table 1. Patients with
DCM had a decreased ejection fraction of 21 6 2% (range
12% to 36%), compared with group III, with an ejection
fraction of 61 6 7% (range 50% to 81%; p , 0.001).
Patients with DCM also had elevated preload (LVEDP and
LVEDV) and afterload (systemic vascular resistance), com-
pared with control subjects. There were no differences in
baseline hemodynamic variables between patients in group I
and those in group II (Table 1).
Effect of intracoronary enalaprilat on beta-adrenergic
contractility. Figure 1 depicts representative steady state
pressure-volume loops and Ees from each group of patients.
Table 1. Baseline Characteristics of Study Group
Group I
(DCM) (n 5 8)
Group II
(DCM)* (n 5 5)
Group III
(Normal) (n 5 5)
Age (yrs) 45 6 3 45 6 6 44 6 4
HR (beats/min) 91 6 3 86 6 5 76 6 9
EF (%) 22 6 3 20 6 3 61 6 7†
CO (l/min) 5.6 6 0.5 5.2 6 0.5 7.8 6 0.9†
SV (ml) 54 6 5 45 6 5 74 6 2†
LVSP (mm Hg) 117 6 8 106 6 4 113 6 5
MAP (mm Hg) 96 6 7 87 6 4 90 6 3
Afterload
SVR (dynes z s z cm25) 1,446 6 67 1,457 6 108 933 6 101†
Ea (mm Hg/ml) 1.7 6 0.2 2.0 6 0.6 1.3 6 0.1
Preload
LVEDP (mm Hg) 19 6 1 21 6 3 9 6 2†
LVEDV (ml) 270 6 25 233 6 39 127 6 15†
Contractility
1dP/dt (mm Hg/s) 1,004 6 123 909 6 97 1,115 6 130
Ees (mm Hg/ml) 0.82 6 0.13 0.64 6 0.23 1.1 6 0.43
Diastole
Tau ln (ms) 53 6 5 54 6 5 38 6 3†
Tau l (ms) 34 6 3 29 6 4 25 6 1
*Baseline Ees and Ea values are available from three of the five patients in group II. †p , 0.05 vs. groups I and II. Data are
presented as the mean value 6 SEM.
CO 5 cardiac output; DCM 5 dilated cardiomyopathy; 1dP/dt 5 peak rate of rise of left ventricular pressure; Ea 5 arterial
elastance; Ees 5 single-beat ventricular elastance; EF 5 ejection fraction; HR 5 heart rate; LVEDP 5 left ventricular
end-diastolic pressure; LVEDV 5 left ventricular end-diastolic volume; LVSP 5 left ventricular systolic pressure; MAP 5 mean
arterial pressure; SV 5 stroke volume; SVR 5 systemic vascular resistance.
Figure 1. Representative steady state pressure-volume data. Depicted are the effects of intracoronary enalaprilat and NG-monomethyl-L-arginine
(L-NMMA) on beta-adrenergic contractility, as assessed by single-beat ventricular elastance (Ees). Group I (with dilated cardiomyopathy [DCM]) and
Group III (normal subjects) received enalaprilat before L-NMMA. Group II (with DCM) received L-NMMA before enalaprilat. In each group, baseline
Ees values are shown as a dashed line. Pressure-volume loops and Ees values are shown at baseline (circles) and in the presence of dobutamine (Dob,
squares), enalaprilat (Enal, triangles) and L-NMMA (diamonds). The numbers in parentheses represent the order of drug infusion.
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The positive inotropic effect of dobutamine was evident as
an increase in the slope of Ees in all three groups (Fig. 1 and
2). Dobutamine increased Ees by 53 6 16% in group I (p ,
0.03) and 56 6 19% in group III (p , 0.05) (Fig. 2).
Ventricular elastance, although measured in only two of the
five patients in group II, increased with dobutamine in both
patients (63 6 1%). In addition, dobutamine increased
1dP/dt by 48 6 8% in group I (p , 0.001), 33 6 10% in
group II (p , 0.05) and 64 6 19% in group III (p , 0.04)
(Fig. 2). The percent increases in 1dP/dt and Ees in
response to dobutamine were not different between the
three groups.
During dobutamine infusion, intracoronary enalaprilat
decreased 1dP/dt in all eight patients in group I, resulting
in a reduction of ;50% in the 1dP/dt response from 49 6
18% to 26 6 12% relative to baseline (p , 0.05) (Fig. 2A).
The attenuation of beta-adrenergic contractility indexed by
Ees was even greater, with a near total elimination of the
augmented Ees response, from 53 6 16% to 22 6 12%
relative to baseline (p , 0.05) (Fig. 2A). In group II,
pretreatment with intracoronary L-NMMA in the presence
of dobutamine caused a small augmentation in 1dP/dt
(36 6 10% vs. 32 6 10%, p , 0.05). Subsequent co-
infusion with intracoronary enalaprilat in this group de-
creased 1dP/dt to a level comparable to that of dobutamine
alone (Table 2, Fig. 2B). Similarly, enalaprilat did not
attenuate beta-adrenergic contractility in patients with nor-
mal left ventricular function (Table 2, Fig. 2C).
Effect of intracoronary L-NMMA on the antiadrenergic
response to enalaprilat. In group I, L-NMMA co-
infusion reversed enalaprilat’s attenuation of beta-
adrenergic contractility, whether assessed by 1dP/dt or Ees.
Co-infusion of L-NMMA increased 1dP/dt from 1,294 6
230 to 1,484 6 263 mm Hg/s (p , 0.05) and increased Ees
from 0.86 6 0.21 to 1.25 6 0.28 mm Hg/ml (p , 0.05)
(Table 2, Fig. 2A). In patients with normal left ventricular
function (group III) in whom enalaprilat had no effect on
beta-adrenergic contractility, L-NMMA co-infusion simi-
larly had no effect on 1dP/dt or Ees (Table 2, Fig. 2C).
Effect of intracoronary enalaprilat on afterload and sys-
temic blood pressure. Table 2 summarizes the effects of
enalaprilat and L-NMMA on afterload and systemic blood
pressure in the presence of dobutamine. In all groups, heart
rate was maintained constant with atrial pacing. In group I
(with DCM), intracoronary enalaprilat did not influence
afterload (Ea and systemic vascular resistance). It did,
however, reduce both left ventricular systolic pressure and
mean arterial pressure in a manner reversible with
L-NMMA co-infusion. When the order of intracoronary
drugs was reversed in group II, L-NMMA increased left
ventricular systolic pressure and mean arterial pressure and
prevented their reduction in response to subsequent intra-
coronary enalaprilat. In patients with normal left ventricular
function, intracoronary enalaprilat had no effect on indexes
of load or systemic pressure.
Effect of intracoronary enalaprilat on diastole. Figure 3
depicts representative pressure-volume data obtained during
diastole. In patients with DCM (group I), intracoronary
enalaprilat reduced LVEDP without affecting LVEDV
(Table 2). This downward shift in the end-diastolic pres-
sure–volume relationship was reversed (group I) and pre-
vented (group II) by L-NMMA. A similar downward shift
in the end-diastolic pressure-volume relationship in re-
sponse to enalaprilat was not observed in control subjects
(group III). Active diastolic relaxation, assessed using two
formulations of tau, was decreased by dobutamine in all
three groups (p , 0.05), but was not affected by subsequent
infusion of enalaprilat or L-NMMA in any group (Table 2).
Effect of intracoronary enalaprilat on stroke work. To
assess the integrated hemodynamic impact of enalaprilat on
beta-adrenergic responsiveness, we examined left ventricular
stroke work. Dobutamine increased left ventricular stroke
work by 51 6 15% (from 5,931 6 1,136 to 8,448 6
1,402 mm Hg z ml, p , 0.05) in patients with DCM (group
Figure 2. Effect of intracoronary enalaprilat (ENAL) and NG-monomethyl-L-arginine (L-NMMA) on the positive inotropic response to dobutamine
(DOB) in patients with dilated cardiomyopathy (DCM) (Groups I and II) and in patients with normal left ventricular function (Group III). Dobutamine
was infused intravenously in all groups to achieve 1dP/dt .30% above baseline. In Groups I and III, enalaprilat was infused intracoronarily for 15 min
before co-infusion with L-NMMA. In Group II, L-NMMA was administered before enalaprilat. Depicted are the percent changes in 1dP/dt (open bars)
and Ees (single-beat elastance; solid bars) with each drug infusion relative to baseline. *p , 0.05 versus dobutamine and versus L-NMMA. †Ees values are
only available for two of the five patients in Group II.
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I). Subsequent infusion with intracoronary enalaprilat
(7,957 6 1,655 mm Hg z ml) and L-NMMA (7,706 6
1,573 mm Hg z ml) did not influence this increase in left
ventricular stroke work. Similar responses were observed in
groups II and III.
DISCUSSION
This study demonstrates that ACE inhibitors attenuate
beta-adrenergic contractility and increase left ventricular
distensibility in patients with idiopathic DCM. These
effects are modulated by myocardial NO production, are
observed in the presence of AT-1 receptor blockade and
occur preferentially in patients with left ventricular systolic
dysfunction. These previously unappreciated properties of
ACE inhibitors may contribute to their therapeutic effects
in the treatment of heart failure and should be considered
when comparing them with other inhibitors of the renin-
angiotensin-aldosterone pathway (13).
Effect of ACE inhibition on beta-adrenergic contractility.
The rationale for performing this study in the presence of
systemic dobutamine was based on observations from hu-
man (3), experimental animal (4) and in vitro studies (14)
that NO inhibits beta-adrenergic myocardial contractility.
The ability of L-NMMA to both reverse and prevent the
negative inotropic response to enalaprilat strongly supports
our hypothesis that the inhibitory effect on beta-adrenergic
contractility is NO-mediated. These findings are consistent
with previous observations that ACE inhibitors increase
cardiac NO levels in both ischemic myocardium (15,16) and
coronary microvessels from failing explanted human hearts
(17).
The effects of ACE inhibition on myocardial contractility
have been difficult to study because of the vasodilatory
properties that alter loading conditions and increase cardiac
output. To circumvent this response, we infused enalaprilat
intracoronarily to achieve higher drug concentrations in the
coronary circulation, thus maximizing direct cardiac effects
and limiting systemic responses. Previous studies with
intracoronary enalaprilat infusion in humans with DCM
have reported either negative (18) or neutral (19) inotropic
effects. The current study differs in that it examined the
cardiac effects of ACE inhibition during beta-adrenergic
stimulation and AT-1 receptor blockade.
In group I (with DCM), enalaprilat reduced left ventric-
ular systolic pressure and mean arterial pressure. The con-
clusion that these hemodynamic changes were secondary to
an attenuation of myocardial contractility is supported not
only by the use of the load-independent index of contrac-
tility Ees, but also by the fact that enalaprilat did not alter
preload (LVEDV) or afterload (Ea and systemic vascular
resistance). The ability of L-NMMA to both reverse and
prevent the effects of enalaprilat supports our hypothesis
that ACE inhibitors attenuate beta-adrenergic contractility
through myocardial NO signaling pathways.Ta
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Effect of ACE inhibition on diastole and chamber com-
pliance. Importantly, enalaprilat reduced LVEDP without
affecting LVEDV. This suggests that, in addition to influ-
encing contractility, enalaprilat also enhanced left ventricu-
lar chamber compliance. In support of this, enalaprilat
caused a downward shift in the end-diastolic pressure-
volume relationship in patients with DCM (group I). A
similar effect has been previously observed with intracoro-
nary administration of sodium nitroprusside (20). The
ability of L-NMMA to both reverse (group I) and prevent
(group II) this downward shift in the end-diastolic pressure-
volume relationship supports the hypothesis that enalapri-
lat’s effect on left ventricular compliance is NO-mediated
(Fig. 3). Interestingly, neither enalaprilat nor L-NMMA
influenced tau, suggesting that the ACE inhibitor and/or
NO-mediated diastolic effects occur preferentially on late
diastolic compliance rather than on early (active) relaxation
in subjects with heart failure.
Myocardial NO signaling in heart failure. Nitric oxide–
mediated attenuation of beta-adrenergic contractility may
contribute to the cardioprotective effects of ACE inhibition.
Beta-adrenergic agonists increase mortality (21), whereas
receptor antagonists improve survival (22,23) in patients
with left ventricular dysfunction. Thus, ACE inhibitors may
exert post-receptor beta-blockade by increasing cardiac NO,
which, in addition to attenuating contractility, may also
decrease myocardial oxygen consumption (24,25).
Our hypothesis that ACE inhibition has a greater NO-
mediated inhibitory effect in patients with heart failure than
in control subjects was based on observations that myocar-
dial NOS activity is elevated in this disease state (26,27). As
a functional correlate, we previously reported that inhibition
of NO synthesis potentiates the response to beta-adrenergic
stimulation in patients with left ventricular dysfunction, but
not in control subjects (6). The present findings raise the
issue of the specific isoform being upregulated in failing
myocardium. An enhanced NO response due to ACE
inhibition suggests an augmented agonist-stimulated path-
way (e.g., bradykinin), rather than agonist-independent NO
signaling (e.g., due to NOS-2 activity). In this regard,
elevations of both NOS-2 and NOS-3 have been reported
in failing myocardium (28,29), and the present results
suggest that increased NOS-3 may have functional signifi-
cance. Alternatively, as we have recently shown in an animal
model, cardiac NO pathway activity may also be regulated
independently of NOS isoform upregulation (5).
Study limitations. There are several limitations that war-
rant mention. First, our observations, made in the acute
setting, may not be applicable to the long-term ACE
inhibitor administration that likely results in other compen-
satory mechanisms. For example, Maisel et al. (30) demon-
strated the reversal of beta-adrenergic receptor downregu-
lation after administration of captopril for two weeks.
Second, it remains possible that the systemic effects of
intracoronary infusions may have influenced loading condi-
tions and contributed to our findings. Our study design
attempted to circumvent this problem by employing an
intracoronary infusion technique to minimize systemic vas-
cular effects (31) and by using a load-independent measure-
ment of contractility (Ees). Finally, to prevent changes in
coronary blood flow from affecting dobutamine concentra-
tions artifactually, dobutamine was administered systemi-
cally to avoid any potential decreases in its concentration
due to enalaprilat or any increases due to L-NMMA.
Figure 3. Effect of enalaprilat (Enal, triangles) and NG-monomethyl-L-arginine (L-NMMA) (diamonds) on the end-diastolic pressure-volume
relationship (EDPVR) in the presence of dobutamine (Dob, squares) in patients with DCM (Groups I and II) and subjects with normal left ventricular
function (Group III). Depicted are representative steady state end-diastolic pressure-volume data. The numbers in parentheses represent the order of drug
infusion for each group. In Group I, enalaprilat resulted in a downward shift of the EDPVR, an effect reversed by subsequent L-NMMA co-infusion. In
Group II, L-NMMA prevented the EDPVR reduction to enalaprilat. Enalaprilat had no effect on EDPVR in Group III.
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Conclusions. Our study demonstrates that ACE inhibitors
attenuate beta-adrenergic contractility and increase left
ventricular distensibility in patients with idiopathic DCM.
These responses result from NO pathway activity and occur
during AT-1 receptor blockade. These previously unappre-
ciated pharmacologic properties of ACE inhibitors may
contribute to the clinical profile of this class of drugs in the
treatment of patients with heart failure and left ventricular
dysfunction.
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